ArticleJournal of molecular histology2026
Aquaporin-9 expression as an independent adverse prognostic marker in diffuse large B-cell lymphoma: an immunohistochemical tissue microarray study.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aquaporins (AQPs) are membrane channel proteins implicated in tumor biology, but their clinicopathological and prognostic relevance in diffuse large B-cell lymphoma (DLBCL) remains insufficiently characterized. This study evaluated the immunohistochemical expression of AQP1, AQP2, AQP8, and AQP9 and their associations with clinicopathological features and survival outcomes in DLBCL. In this retrospective cohort study, formalin-fixed, paraffin-embedded tissue samples from 164 DLBCL cases diagnosed at Mansoura University Oncology Center between 2011 and 2022 were analyzed using tissue microarray-based immunohistochemistry. Associations between marker expression and clinicopathological variables were assessed using appropriate comparative tests. Overall survival (OS) and disease-free survival (DFS) were analyzed using Kaplan-Meier methods and Cox proportional hazards regression. A sensitivity Cox analysis was additionally performed to assess whether the association of AQP9 with overall survival persisted after adjustment for rituximab exposure. Positivity for AQP1, AQP2, AQP8, and AQP9 was detected in 9.8% (16/164), 1.8% (3/164), 0.6% (1/164), and 11.6% (19/164) of cases, respectively. AQP1 positivity was associated with higher International Prognostic Index (IPI) risk category (P = 0.007) and lower hemoglobin levels (P = 0.012), but not with significant differences in survival. AQP9 expression was significantly associated with inferior OS, with a median OS of 20.7 months in AQP9-positive cases versus 78.6 months in AQP9-negative cases (log-rank P = 0.002). In multivariable analysis, AQP9 remained an independent adverse predictor of mortality (HR 2.44, 95% CI 1.35-4.40; P = 0.003). This association remained significant in a sensitivity model additionally adjusting for rituximab exposure (HR 2.26, 95% CI 1.25-4.09; P = 0.007). None of the evaluated markers significantly predicted DFS. AQP9 expression identifies a subgroup of DLBCL patients with significantly poorer overall survival and may provide prognostic information beyond conventional clinical risk stratification. In contrast, AQP1 was associated with adverse baseline features but had no significant impact on survival, while AQP2 and AQP8 were rarely expressed. Larger multi-center studies are warranted to validate the prognostic role of AQP9 in DLBCL.
Indexed as
Identifiers
42098514What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.